Contrast Ultrasound Assessment of Perfusion Changes After Peripheral Artery Revascularization



Status:Recruiting
Conditions:Peripheral Vascular Disease
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:19 - 99
Updated:8/25/2018
Start Date:June 1, 2018
End Date:December 31, 2019
Contact:Jonathan R Lindner, MD
Email:lindnerj@ohsu.edu
Phone:503 494-9191

Use our guide to learn which trials are right for you!

This study represents an important step to validate the use of contrast-enhanced ultrasound
(CEU) as a clinical research tool that can be used as a biologic readout of new therapies for
Peripheral Artery Disease (PAD), and as a clinically-reasonable method for assessing impact
of revascularization. The primary aim is to establish that CEU limb perfusion imaging can be
used to accurately assess therapeutic improvements in tissue perfusion that are linked to
symptom improvement.

The study will be performed in patients with known history of PAD that are scheduled to
undergo either surgical or percutaneous revascularization. Limb rest-stress CEU perfusion
imaging will be performed before and 3-4 weeks after revascularization. Quantitative
measurements of pre-revascularization perfusion, post-revascularization perfusion, and change
in perfusion will be compared to symptom status (Rutherford classification and PAD [Criqui]
questionnaire) at each study point, and to data on time to onset of claudication on an
upright treadmill exercise study (Gardiner protocol). Results of angiography will be scored
and allow determination of the relationship between angiographic severity of disease and
exercise perfusion.

Inclusion Criteria:

1. History of symptomatic PAD

2. Rutherford score <6

3. Age ≥18 y.o.

4. Scheduled to undergo surgical or percutaneous revascularization

Exclusion Criteria:

1. Major medical illness affecting the limb other than PAD (muscle disease, neuromuscular
disease, blood diseases).

2. Pregnant or lactating females (- HCG in women of child bearing age)

3. Hypersensitivity to any ultrasound contrast agent

4. Evidence right-to-left, bi-directional, or transient cardiac shunt; unexplained
pulmonary hypertension (PA systolic pressure >40 mm Hg) or more than moderate
reduction in left ventricular systolic function identified on screening echo.

5. Allergy to eggs

6. Inability to perform modest plantar flexion exercise
We found this trial at
1
site
Portland, Oregon 97201
Principal Investigator: Jonathan R Lindner, MD
Phone: 503-494-8750
?
mi
from
Portland, OR
Click here to add this to my saved trials